Revolution Medicines is rated a Hold due to valuation concerns, uncertain acquisition prospects, and solo commercialization.

Shares of Revolution Medicines RVMD were rising in pre-market today after the company reported full results from the phase ...

On Monday, Purple Biotech Ltd (NASDAQ:PPBT) reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in ...

Purple Biotech PPBT, a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead candidate, CM24, for treating pancreatic ductal adenocarcinoma (“PDAC”) ...

Vaccinex will describe use of the new “Antigen Virus” application, a potential tool to improve antibody development for high complexity, hard-to-drug targets, such as G-protein coupled receptors ...